2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Breast Neoplasms
48
Neoplasms
43
Depression
31
Fatigue
30
Prostatic Neoplasms
23
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Lymphoma, Follicular
18
Lymphoma, Large B-Cell, Diffuse
17
Multiple Myeloma
16
Carcinoma, Non-Small-Cell Lung
16
Lymphoma, Non-Hodgkin
15
Lung Neoplasms
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Lymphoma, Mantle-Cell
14
Leukemia, Myeloid, Acute
14
Hodgkin Disease
14
Colorectal Neoplasms
14
Burkitt Lymphoma
14
Anxiety Disorders
14
Pain
13
Lymphoma, B-Cell, Marginal Zone
13
Lymphoma, Large-Cell, Immunoblastic
12
Lymphoma
11
Leukemia, Myeloid, Chronic-Phase
11
Head and Neck Neoplasms
11
Blast Crisis
11
Lymphoma, T-Cell, Cutaneous
10
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
10
Leukemia, Myeloid, Accelerated Phase
10
Leukemia, Hairy Cell
10
Interventions
relacorilant
5
Nutrition Assessment
4
Hydrochlorothiazide
4
Bevacizumab
3
Amlodipine
3
aliskiren
2
Osilodrostat
2
Lisinopril
2
Labetalol
2
Angiotensin-Converting Enzyme Inhibitors
2
Adrenalectomy
2
ziprasidone
1
sacubitril and valsartan sodium hydrate drug combination
1
pembrolizumab
1
pazopanib
1
lutetium Lu 177 dotatate
1
ganirelix
1
gallium Ga 68 dotatate
1
fimasartan
1
enzalutamide
1
clevidipine
1
cediranib
1
bicalutamide
1
benazepril
1
Zolpidem
1
Warfarin
1
Vitamin D
1
Vecuronium Bromide
1
Vancomycin
1
Urine Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hypertension
×
Therapeutics
×
Clear all
NCT03443635
2022-04-29
CHOP
Tulane University
Phase 1/2
Completed
7,192 enrolled
7 charts